tucatinib sold brand name tukysa anticancer medication used treatment breast small molecule inhibitor developed array biopharma licensed cascadian therapeutics formerly oncothyreon subsequently part seattle common side effects include diarrhea palmarplantar erythrodysesthesia burning tingling discomfort hands feet nausea fatigue hepatotoxicity liver damage vomiting stomatitis inflammation mouth lips decreased appetite abdominal pain headache anemia tucatinib may cause harm developing fetus tucatinib approved medical use united states april australia august european union february tucatinib kinase inhibitor indicated combination trastuzumab capecitabine treatment adults advanced unresectable metastatic breast cancer including brain metastases received one prior regimens metastatic european union indicated combination trastuzumab capecitabine treatment adults locally advanced metastatic breast cancer received least two prior treatment january us food drug administration fda granted accelerated approval tucatinib combination trastuzumab ras wildtype unresectable metastatic colorectal cancer progressed following fluoropyrimidine oxaliplatin irinotecanbased two early stage clinical trials reported encouraging results options enroll subjects central nervous system cns phase randomized doubleblinded placebocontrolled study tucatinib combination trastuzumab capecitabine patients pretreated unresectable locally advanced metastatic breast april us food drug administration fda approved tucatinib combination chemotherapy trastuzumab capecitabine treatment adults advanced forms breast cancer cant removed surgery spread parts body including brain received one prior fda collaborated australian therapeutic goods administration tga health canada health sciences authority hsa singapore swissmedic smc switzerland first project orbis partnership fda hsa april application still review tucatinib kinase inhibitor meaning blocks type enzyme kinase helps prevent cancer cells tucatinib approved treatment adults taken one regimens metastatic fda approved tucatinib based results trial enrolling subjects advanced unresectable metastatic breast cancer prior treatment trastuzumab pertuzumab adotrastuzumab emtansine subjects previously treated stable brain metastases well previously treated growing untreated brain metastases eligible clinical trial enrolled subjects brain metastases start subjects received either tucatinib mg twice daily plus trastuzumab capecitabine tucatinib arm placebo plus trastuzumab capecitabine control arm primary endpoint progressionfree survival pfs amount time growth tumor assessed blinded independent central review evaluated initial randomized median pfs subjects received tucatinib trastuzumab capecitabine months ci compared months ci subjects received placebo trastuzumab capecitabine hr ci overall survival pfs subjects brain metastases baseline key secondary median overall survival subjects received tucatinib trastuzumab capecitabine months ci compared months ci subjects received placebo trastuzumab capecitabine hr ci median pfs subjects brain metastases baseline received tucatinib trastuzumab capecitabine months ci compared months ci subjects received placebo trastuzumab capecitabine hr fda granted application tucatinib priority review breakthrough therapy fast track orphan drug fda granted approval tukysa seattle genetics tucatinib denied entry australian pharmaceutical benefits scheme march incremental cost effectiveness ratio unacceptably high proposed tucatinib approved medical use united states april tucatinib approved medical use australia august december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product tukysa intended treatment locally advanced metastatic breast applicant medicinal product seagen tucatinib approved medical use european union february tucatinib international nonproprietary httpsenwikipediaorgwikitucatinib